

ETFS S&P Biotech ETF

ARSN 628 037 105

**Condensed Interim Financial Report - For the half-year ended 31
December 2021**

ETFS S&P Biotech ETF

ARSN 628 037 105

Condensed Interim Financial Report - For the half-year ended 31 December 2021

Contents

	Page
Directors' Report	1
Auditor's Independence Declaration	4
Condensed Statement of Profit or Loss and Other Comprehensive Income	5
Condensed Statement of Financial Position	6
Condensed Statement of Changes in Equity	7
Condensed Statement of Cash Flows	8
Notes to the Financial Statements	9
Directors' Declaration	15
Independent Auditor's Report	16

Directors' Report

The directors of ETFS Management (AUS) Limited (the "Responsible Entity"), the Responsible Entity of ETFS S&P Biotech ETF (the "Fund"), present their interim report together with the condensed interim financial statements of the Fund, for the half-year ended 31 December 2021 and the auditor's report thereon.

Fund Objectives

The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index (the "Index").

The Fund aims to track the performance of the Index by holding all of the shares that make up the Index, in the proportion closely mirroring the Index. All assets of the Fund are held in segregated accounts with the Custodian, JPMorgan Chase Bank N.A. (Sydney Branch).

The Fund is an Exchange Traded Fund ("ETF") and can be traded by investors on the Australian Securities Exchange ("ASX"); ETFs can be bought and sold like any other share through normal brokerage accounts.

Principal Activities

The Fund was constituted on 22 August 2018 and commenced its operations on 8 November 2018. The Fund is currently listed on the ASX. The admission date was 12 November 2018.

The Fund invested in accordance with the provisions of the Fund's Constitution. There were no significant changes in the nature of the Fund's activities during the half-year ended 31 December 2021.

The Fund did not have any employees during the half-year ended 31 December 2021.

Directors

The following persons held office as directors of the Responsible Entity during the half-year or since the end of the half-year and up to the date of this report:

Director

Vince Fitzgerald (appointed 16 December 2014)

Graham Tuckwell (appointed 16 December 2014)

Mark Weeks (appointed 25 August 2020)

Review and Results of Operations

During the half-year, the Fund continued to invest funds in accordance with target asset allocations as set out in the governing documents of the Fund and in accordance with the provisions of the Fund's Constitution.

Results

The performance of the Fund, as represented by the results of its operations, was as follows:

	Half-year ended 31 December 2021	Half-year ended 31 December 2020
	AUD'000	AUD'000
Profit/(loss) for the half-year	(9,044)	3,197
Distributions paid and payable	-	-

Directors' Report (continued)

Review and Results of Operations (continued)

Returns

The table below demonstrates the performance of the Fund as represented by the total return.

	Returns*		
	1 July 2021 to 31 December 2021 %	1 July 2020 to 31 December 2020 %	1 July 2019 to 31 December 2019 %
ETFS S&P Biotech ETF returns	(14.73)	12.01	8.34

* Returns (after fees) are calculated on the assumption that all distributions are reinvested in the Fund, and include the effect of compounding.

Significant Changes in State of Affairs

Since the World Health Organisation declared COVID-19 a global pandemic in March 2020, there has been a significant impact to the both local and global economies and to society. As at the reporting date, the resulting impact on the global and domestic market remains uncertain. Management have taken into account the impacts of the pandemic when preparing these financial statements reflected in the valuation of the investments and the financial results for the half-year ended 31 December 2021.

In the opinion of the directors, there were no other significant changes in the state of affairs of the Fund that occurred during the financial half-year under review.

Matters Subsequent to the end of the half-year

Since the balance date, the associated economic impacts of COVID-19 remain uncertain. As the investments are measured at their 31 December 2021 fair values in the condensed interim financial report, any change in values subsequent to the end of the reporting period is not reflected in the Condensed Statement of Profit or Loss and Other Comprehensive Income or the Condensed Statement of Financial Position.

Since the end of the reporting period, the Fund's net asset value has decreased by more than 10% due to changes in fair value of investments held. The movement is a result of implementation of the investment strategy as set out in the Fund's product disclosure statement.

No other matter or circumstance has arisen since 31 December 2021 that has significantly affected, or may significantly affect:

- (i) the operations of the Fund in future financial periods, or
- (ii) the results of those operations in future financial periods, or
- (iii) the state of affairs of the Fund in future financial periods.

Rounding of Amounts

The Fund is a registered scheme of a kind referred to in ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, issued by the Australian Securities and Investments Commission relating to the "rounding off" of amounts in the directors' report and financial statements. Amounts in the directors' report and the financial statements have been rounded to the nearest thousand dollars in accordance with ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, unless otherwise indicated.

Directors' Report (continued)

Auditor's Independence Declaration

A copy of the auditor's independence declaration as required under Section 307C of the *Corporations Act 2001* is set out on page 4.

This report is made in accordance with a resolution of the directors.

DocuSigned by:
Graham Tuckwell
DB8639C4F290469...

Graham Tuckwell

Director

Melbourne

10 March 2022



Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

To the Directors of ETFS Management (AUS) Limited as Responsible Entity of
ETFs S&P Biotech ETF

I declare that, to the best of my knowledge and belief, in relation to the review of ETFs S&P Biotech
ETF for the half-year ended 31 December 2021 there have been:

- i. no contraventions of the auditor independence requirements as set out in the
Corporations Act 2001 in relation to the review; and
- ii. no contraventions of any applicable code of professional conduct in relation to the review.

KPMG

Nic Buchanan

Partner

Sydney

10 March 2022

ETF S&P Biotech ETF
Condensed Statement of Profit or Loss and Other Comprehensive Income
For the half-year ended 31 December 2021

		Half-year ended 31 December 2021 AUD'000	Half-year ended 31 December 2020 AUD'000
<i>Investment income</i>			
Dividend/distribution income		21	9
Net gains/(losses) on financial instruments at fair value through profit or loss (including FX gains/(losses))	4	<u>(8,917)</u>	<u>3,250</u>
<i>Total net investment income/(loss)</i>		<u>(8,896)</u>	<u>3,259</u>
<i>Expenses</i>			
Management fees	7	132	50
Transaction costs		<u>16</u>	<u>12</u>
<i>Total operating expenses</i>		<u>148</u>	<u>62</u>
<i>Profit/(loss) for the half-year</i>		(9,044)	3,197
Other comprehensive income		<u>-</u>	<u>-</u>
<i>Total comprehensive income for the half-year</i>		<u>(9,044)</u>	<u>3,197</u>

The above Condensed Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

ETFS S&P Biotech ETF
Condensed Statement of Financial Position
As at 31 December 2021

		As at 31 December 2021	As at 30 June 2021
	Notes	AUD'000	AUD'000
Assets			
Cash and cash equivalents		447	1,434
Financial assets at fair value through profit or loss	6	56,268	51,515
Receivables		<u>7</u>	<u>4,484</u>
Total assets		<u>56,722</u>	<u>57,433</u>
Liabilities			
Distribution payable		-	5,146
Payables		<u>24</u>	<u>1,390</u>
Total liabilities		<u>24</u>	<u>6,536</u>
Net assets attributable to unitholders - equity	5	<u>56,698</u>	<u>50,897</u>

The above Condensed Statement of Financial Position should be read in conjunction with the accompanying notes.

ETFS S&P Biotech ETF
Condensed Statement of Changes in Equity
For the half-year ended 31 December 2021

		Half-year ended 31 December 2021 AUD'000	Half-year ended 31 December 2020 AUD'000
	Notes		
<i>Total equity at the beginning of the financial half-year</i>	5	50,897	11,099
<i>Comprehensive income for the half-year</i>			
Profit/(loss) for the half-year		(9,044)	3,197
Other comprehensive income		<u>-</u>	<u>-</u>
<i>Total comprehensive income for the half-year</i>		<u>(9,044)</u>	<u>3,197</u>
<i>Transactions with unitholders</i>			
Applications	5	14,098	20,240
Units issued upon reinvestment of distributions	5	<u>747</u>	<u>118</u>
<i>Total transactions with unitholders</i>		<u>14,845</u>	<u>20,358</u>
<i>Total equity at the end of the financial half-year</i>	5	<u>56,698</u>	<u>34,654</u>

The above Condensed Statement of Changes in Equity should be read in conjunction with the accompanying notes.

ETFS S&P Biotech ETF
Condensed Statement of Cash Flows
For the half-year ended 31 December 2021

	Half-year ended 31 December 2021	Half-year ended 31 December 2020
Notes	AUD'000	AUD'000
<i>Cash flows from operating activities</i>		
Proceeds from sale of financial instruments	25,201	10,416
Payments for purchase of financial instruments	(35,779)	(27,808)
Transaction costs paid	(16)	(12)
Dividends/distributions received	21	9
Other income received	-	1
Management fees paid	(129)	(41)
Operating expenses paid	<u>(1)</u>	<u>(2)</u>
<i>Net cash inflow/(outflow) from operating activities</i>	<u>(10,703)</u>	<u>(17,437)</u>
<i>Cash flows from financing activities</i>		
Proceeds from applications by unitholders	14,098	20,240
Distributions paid	<u>(4,399)</u>	<u>(1,099)</u>
<i>Net cash inflow/(outflow) from financing activities</i>	<u>9,699</u>	<u>19,141</u>
<i>Net increase/(decrease) in cash and cash equivalents</i>	(1,004)	1,704
Cash and cash equivalents at the beginning of the half-year	1,434	95
Effects of foreign currency exchange rate changes on cash and cash equivalents	<u>17</u>	<u>(22)</u>
<i>Cash and cash equivalents at the end of the half-year</i>	<u>447</u>	<u>1,777</u>
Non cash financing activities	5 <u>747</u>	<u>118</u>

The above Condensed Statement of Cash Flows should be read in conjunction with the accompanying notes.

1 General Information

These condensed interim financial statements cover ETF S&P Biotech ETF (the “Fund”) as an individual entity. The Fund was constituted on 22 August 2018 and commenced its operations on 8 November 2018. The Fund is currently listed on the ASX. The admission dates was 12 November 2018.

The Fund is domiciled in Australia and is a for-profit entity.

The Responsible Entity of the Fund is ETF Management (AUS) Limited (the “Responsible Entity”). The Responsible Entity’s registered office is Level 7, 50 King Street, Sydney NSW 2000 Australia.

The condensed interim financial report was authorised for issue by the directors on 10 March 2022. The directors of the Responsible Entity have the power to amend and reissue the condensed interim financial statements.

The condensed interim financial statements are presented in Australian Dollars, which is the Fund’s functional currency.

2 Basis of Preparation and Accounting Policies

The condensed interim financial statements are general purpose financial statements prepared in accordance with the *Corporations Act 2001* and AASB 134 *Interim Financial Reporting*. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 *Interim Financial Reporting*.

The condensed interim financial statements do not include all the notes of the type normally included in an annual financial report. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2021 and any public announcements made during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

The Fund is a registered scheme of a kind referred to in ASIC Corporations (Rounding in Financial/Directors’ Reports) Instrument 2016/191, issued by the Australian Securities and Investments Commission relating to the “rounding off” of amounts in the directors’ report and financial statements. Amounts in the directors’ report and the financial statements have been rounded to the nearest thousand dollars in accordance with ASIC Corporations (Rounding in Financial/Directors’ Reports) Instrument 2016/191, unless otherwise indicated.

Accounting policies and methods of computation adopted in the preparation of the condensed interim financial statements are consistent with those adopted and disclosed in the Fund’s 2021 annual financial report for the financial year ended 30 June 2021.

There are no new standards, interpretations or amendments to existing standards that are effective for the first time for the financial half-year beginning 1 July 2021 that would be expected to have a material impact on the Fund.

3 Financial Risk Management

(a) Fair Values of Financial Assets and Liabilities

The carrying amounts of the Fund’s assets and liabilities at the end of each reporting period approximate their fair values.

Financial assets and liabilities at fair value through profit or loss are measured initially at fair value. Transaction costs on financial assets and financial liabilities at fair value through profit or loss are expensed immediately. Subsequent to initial recognition, all instruments at fair value through profit or loss are measured at fair value with changes in their fair value recognised in the Condensed Statement of Profit or Loss and Other Comprehensive Income.

The carrying value less loss allowance of other receivables and payables are assumed to approximate their fair value. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Fund for similar financial instruments.

3 Financial Risk Management (continued)

(a) Fair Values of Financial Assets and Liabilities (continued)

(i) Fair value in an active market

The fair value of financial assets and liabilities traded in active markets is based on their last traded prices at the end of the reporting period without any deduction for estimated future selling costs.

The Fund values its investments in accordance with the accounting policies set out in the Fund's 2021 annual financial report. For the majority of its investments, the Fund relies on information provided by independent pricing services for the valuation of its investments.

The quoted market price used for financial assets and financial liabilities held by the Fund is the last traded market price. Where the last traded price does not fall within the bid-ask spread, an assessment is performed by the Responsible Entity to determine the appropriate valuation price to use that is most representative of fair value.

A financial instrument is regarded as quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency and those prices represent actual regularly occurring market transactions on an arm's length basis.

(ii) Fair value in an inactive or unquoted market

The fair value of financial assets and liabilities that are not traded in an active market is determined using valuation techniques. These include the use of recent arm's length market transactions, reference to the current fair value of a substantially similar other instrument, discounted cash flow techniques, option pricing models or any other valuation technique that provides a reliable estimate of prices obtained in actual market transactions.

Where discounted cash flow techniques are used, estimated future cash flows are based on management's best estimates and the discount rate used is a market rate at the end of the reporting period applicable for an instrument with similar terms and conditions.

For other pricing models, inputs are based on market data at the end of the reporting period. Fair values for unquoted equity investments are estimated, if possible, using applicable price/earnings ratios for similar listed companies adjusted to reflect the specific circumstances of the issuer.

The fair value of derivatives that are not exchange traded is estimated at the amount that the Fund would receive or pay to terminate the contract at the end of the reporting period taking into account current market conditions (volatility and appropriate yield curve) and the current creditworthiness of the counterparties. The fair value of a forward foreign exchange contract is determined as a net present value of estimated future cash flows, discounted at appropriate market rates as at the valuation date.

(b) Fair Value Hierarchy

The Fund classifies fair value measurements using a fair value hierarchy that reflects the subjectivity of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).
- Level 3 Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs).

The level in the fair value hierarchy within which the fair value measurement is categorised in its entirety is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgment, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgment by the Responsible Entity. The Responsible Entity considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

3 Financial Risk Management (continued)

(b) Fair Value Hierarchy (continued)

The following tables present the Fund's financial assets and liabilities (by class) measured at fair value according to the fair value hierarchy at 31 December 2021 and 30 June 2021.

As at 31 December 2021	Level 1 AUD'000	Level 2 AUD'000	Level 3 AUD'000	Total AUD'000
Financial Assets				
Financial assets at fair value through profit or loss				
Listed equity securities	<u>56,268</u>	-	-	<u>56,268</u>
Total	<u>56,268</u>	<u>-</u>	<u>-</u>	<u>56,268</u>

As at 30 June 2021	Level 1 AUD'000	Level 2 AUD'000	Level 3 AUD'000	Total AUD'000
Financial Assets				
Financial assets at fair value through profit or loss				
Forward currency contracts	-	1	-	1
Listed equity securities	<u>51,512</u>	-	<u>2</u>	<u>51,514</u>
Total	<u>51,512</u>	<u>1</u>	<u>2</u>	<u>51,515</u>

Investments whose values are based on quoted market prices in active markets, and therefore classified within level 1, include active listed equities and trusts.

Financial instruments that trade in markets that are not considered to be active but are valued based on quoted market prices, dealer quotations or alternative pricing sources supported by observable inputs are classified within level 2. These include over-the-counter derivatives. As level 2 investments include positions that are not traded in active markets and/or are subject to transfer restrictions, valuations may be adjusted to reflect illiquidity and/or non-transferability, which are generally based on available market information.

Investments classified within level 3 have significant unobservable inputs, as they are infrequently traded. As observable prices are not available for these securities, the Responsible Entity has used valuation techniques to derive fair value.

(i) Transfers between levels

There were no transfers between levels for recurring fair value measurements during the period ended 31 December 2021.

The following tables present the transfers between levels for year ended 30 June 2021:

At 30 June 2021	Level 1 \$'000	Level 2 \$'000	Level 3 \$'000
Transfers between levels 2 and 3:			
Listed equity securities	-	(2)	2

3 Financial Risk Management (continued)

(b) Fair Value Hierarchy (continued)

(ii) Fair value measurement using significant unobservable inputs (level 3)

The following table presents the movement in level 3 instruments for the half-year ended 31 December 2021 by class of financial instrument.

31 December 2021	Listed equity securities \$'000
Opening balance	2
Purchases	-
Sales	(2)
Transfers into Level 3	-
Gains/(losses) recognised in the Statement of Profit or Loss and Other Comprehensive Income	-
Closing balance	-
Total unrealised gains/(losses) for the year included in the Statement of Profit or Loss and Other Comprehensive Income for financial assets and liabilities held at the end of the half-year	-
	Listed equity securities \$'000
30 June 2021	
Opening balance	-
Purchases	-
Sales	-
Gains/(losses) recognised in the Statement of Profit or Loss and Other Comprehensive Income	-
Transfers into Level 3	2
Closing balance	2
Total unrealised gains/(losses) for the year included in the Statement of Profit or Loss and Other Comprehensive Income for financial assets and liabilities held at the end of the year	2

4 Net Gains/(Losses) on Financial Instruments at Fair Value Through Profit or Loss

The net gains/(losses) recognised in relation to financial assets and financial liabilities at fair value through profit or loss:

	Half-year ended 31 December 2021 AUD'000	Half-year ended 31 December 2020 AUD'000
Net unrealised gain/(loss) on financial assets and liabilities at fair value through profit or loss (including FX gains/(losses))	(7,760)	252
Net realised gain/(loss) on financial assets and liabilities at fair value through profit or loss (including FX gains/(losses))	(1,157)	2,998
Net gains/(losses) on financial instruments at fair value through profit or loss (including FX gains/(losses))	(8,917)	3,250

5 Net Assets Attributable to Unitholders

Under AASB 132 *Financial instruments: Presentation*, puttable financial instruments meet the definition of a financial liability to be classified as equity where certain strict criteria are met. The Fund shall classify a financial instrument as an equity instrument from the date when the instrument has all the features and meets the conditions.

The Fund meets the criteria set out under AASB 132 and net assets attributable to unitholders is classified as equity.

ETFS S&P Biotech ETF
Notes to the Financial Statements
For the half-year ended 31 December 2021

5 Net Assets Attributable to Unitholders (continued)

As stipulated within the Fund's Constitution, each unit represents a right to an individual share in the Fund and does not extend to a right to the underlying assets of the Fund. There are no separate classes of units and each unit has the same rights attaching to it as all other units of the Fund.

Movement in number of units and net assets attributable to unitholders during the half-year were as follows:

	Half-year ended		Half-year ended	
	31 December 2021		31 December 2020	
	No.'000	AUD'000	No.'000	AUD'000
Opening balance	822	50,897	180	11,099
Profit/(loss) for the half-year	-	(9,044)	-	3,197
Applications	240	14,098	320	20,240
Units issued upon reinvestment of distributions	12	747	2	118
Closing balance	<u>1,074</u>	<u>56,698</u>	<u>502</u>	<u>34,654</u>

Capital Risk Management

The Fund manages its net assets attributable to unitholders as capital. The amount of net assets attributable to unitholders can change significantly on a daily basis as the Fund is subject to daily applications and redemptions at the discretion of unitholders.

The Fund monitors the level of daily applications and redemptions relative to the liquid assets in the Fund. As of 31 December 2021, the capital of the Fund is represented in the net assets attributable to unitholders table.

In the event of a significant redemption, the Fund's Constitution allows the delay of payment beyond the usual redemption timeframe but no later than the maximum number of days specified in the Constitution for satisfying redemption requests. Further, in certain circumstances such as disrupted markets, the Constitution allows payment to be delayed beyond the maximum number of days.

6 Financial Assets at Fair Value Through Profit or Loss

	As at 31 December 2021 AUD'000	As at 30 June 2021 AUD'000
Financial assets at fair value through profit or loss		
Forward currency contracts	-	1
Listed equity securities	<u>56,268</u>	<u>51,514</u>
Total financial assets at fair value through profit or loss	<u>56,268</u>	<u>51,515</u>

7 Management Fee

The management fee is calculated by applying a fixed percentage to the value of units in issue on a daily basis, equivalent to 0.45% per annum, inclusive of GST, and net of applicable RITC. The management fee is paid in Australian Dollars on a monthly basis.

8 Segment Information

The Fund operates solely in the business of providing investors with the performance of the market, before fees and expenses, as represented by the S&P Biotechnology Select Industry Index. The Responsible Entity, which is the chief operating decision maker for the purposes of assessing performance and determining the allocation of resources, ensures that the Fund's holdings and performance are in accordance with the S&P Biotechnology Select Industry Index. Accordingly, no additional qualitative or quantitative disclosures are required.

9 Events Occurring After the Reporting Period

The uncertainty around COVID-19 continues to present social and economic challenges and the resulting impact on the global and domestic market remains uncertain. Since the reporting date, there have been no significant changes to the valuation of the Fund's investments as a result of COVID-19.

Since the end of the reporting period, the Fund's net asset value has decreased by more than 10% due to changes in fair value of investments held. The movement is a result of implementation of the investment strategy as set out in the Fund's product disclosure statement.

No other significant events have occurred since the end of the reporting period up to the date of signing the condensed interim financial report which would impact on the financial position of the Fund disclosed in the Condensed Statement of Financial Position as at 31 December 2021 or on the results and cash flows of the Fund for the half-year ended on that date.

Directors' Declaration

In the opinion of the directors of the Responsible Entity of ETFS S&P Biotech ETF (the Fund):

- (a) the condensed interim financial statements and notes set out on pages 5 to 14 are in accordance with the *Corporations Act 2001*, including:
 - (i) complying with Accounting Standards AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*; and
 - (ii) giving a true and fair view of the Fund's financial position as at 31 December 2021 and of its performance for the financial half-year ended on that date; and
- (b) there are reasonable grounds to believe that the Fund will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the Responsible Entity made pursuant to s.303(5) of the *Corporations Act 2001*.

On behalf of the directors of the Responsible Entity.

DocuSigned by:

DB8639C4F290469...

Graham Tuckwell
Director

Melbourne
10 March 2022



Independent Auditor's Review Report

To the unitholders of ETFS S&P Biotech ETF

Conclusion

We have reviewed the accompanying *Condensed Interim Financial Report* of ETFS S&P Biotech ETF (the Scheme).

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the Condensed Interim Financial Report of ETFS S&P Biotech ETF does not comply with the *Corporations Act 2001*, including:

- giving a true and fair view of the Scheme's financial position as at 31 December 2021 and of its performance for the half-year ended on that date; and
- complying with *Australian Accounting Standard AASB 134 Interim Financial Reporting* and the *Corporations Regulations 2001*.

The *Condensed Interim Financial Report* comprises:

- Condensed statement of financial position as at 31 December 2021
- Condensed statement of profit or loss and other comprehensive income, Condensed statement of changes in equity and Condensed statement of cash flows for the half-year ended on that date
- Notes 1 to 9 comprising a summary of significant accounting policies and other explanatory information
- The Directors' Declaration.

The *half-year* is the 6 months ended on 31 December 2021.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report.

We are independent of the Scheme in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the *Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with these requirements.



Responsibilities of the Directors for the Condensed Interim Financial Report

The Directors of the ETFS Management (AUS) Limited (the Responsible Entity) are responsible for:

- the preparation of the Condensed Interim Financial Report that gives a true and fair view in accordance with *Australian Accounting Standards* and the *Corporations Act 2001*
- such internal control as the Directors determine is necessary to enable the preparation of the Condensed Interim Financial Report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Review of the Condensed Interim Financial Report

Our responsibility is to express a conclusion on the Condensed Interim Financial Report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the Condensed Interim Financial Report does not comply with the *Corporations Act 2001* including giving a true and fair view of the Scheme's financial position as at 31 December 2021 and its performance for the Half-Year ended on that date, and complying with *Australian Accounting Standard AASB 134 Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a Condensed Interim Period Financial Report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with *Australian Auditing Standards* and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

KPMG

Nic Buchanan

Partner

Sydney

10 March 2022